Condition
Terminally Ill
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05734781CompletedPrimary
End-of-life Communication From a Chinese Perspective
NCT02036281Phase 1CompletedPrimary
A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain
NCT00982995Phase 2Terminated
Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
NCT00121004Completed
A Study to Tailor Advance Directives
Showing all 4 trials